BACKGROUND: Osmotic release oral system (OROS  ) @entity10748 is a potent, long-acting opioid analgesic, effective and safe for controlling @entity5 in @entity1 who have received other strong opioids. To date, few studies have examined the efficacy of @entity10748 for @entity158 relief in opioid-naive @entity5 @entity1 . OBJECTIVES: A prospective, open-label, multicentre trial was conducted to determine the efficacy and tolerability of OROS @entity10748 as a single and front-line opioid therapy for @entity1 experiencing moderate to severe @entity5 . METHODS: OROS @entity10748 was administered to @entity1 who had not previously received strong, long-acting opioids. The baseline evaluation (visit 1) was followed by two evaluations (visits 2 and 3) performed two and 14 weeks later, respectively. The starting dose of OROS @entity10748 was 4_mg   day and was increased every two days when @entity158 control was insufficient. Immediate-release @entity10748 was the only accepted alternative strong opioid for relief of @entity158 . The efficacy, safety and tolerability of OROS @entity10748 , including the effects on quality of life, and @entity1 ' and investigators' global impressions on @entity158 relief were evaluated. The primary end point was @entity158 ( @entity158 ) at visit 2 relative to visit 1 (expressed as % @entity158 ). RESULTS: A total of 107 @entity1 were enrolled in the present study. An improvement in @entity158 intensity of >50% (>= 50% @entity158 ) was observed in 51.0% of the full analysis set and 58.6% of the per-protocol set. The mean @entity158 score, measured using a numerical rating scale, was significantly reduced after two weeks of treatment, and most adverse events were manageable. Quality of life also improved, and >70% of @entity1 and investigators were satisfied with the treatment. CONCLUSIONS: OROS @entity10748 provided effective @entity158 relief and improved quality of life in opioid-naive @entity5 @entity1 . As a single and front-line treatment, OROS @entity10748 delivered rapid @entity158 control.

A prospective multicentre study to evaluate the efficacy and tolerability of osmotic release oral system (OROS  ) XXXX in opioid-naive @entity5 @entity1 : Results of the Korean South West Oncology Group study.

@entity5 :: ('MESH:D009369', 'Disease') :: ['cancer', 'cancer pain'] @entity1 :: ('9606', 'Species') :: ['patients'] @entity10748 :: ('MESH:D004091', 'Chemical') :: ['hydromorphone'] @entity158 :: ('MESH:D010146', 'Disease') :: ['breakthrough pain', 'PID', 'pain', 'pain intensity difference']
@entity10748 :: (MESH:D004091,Chemical) :: ['hydromorphone']
